Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.64 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.64 |
| ▸ | NPY2R | P49146 | 8/20 | 0.62 |
| ▸ | NPY4R | P50391 | 8/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.62 |
| ▸ | NPY1R | P25929 | 6/20 | 0.62 |
| ▸ | TFPI | P10646 | 6/20 | 0.59 |
| ▸ | REN | P00797 | 3/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL513519 | 0.87 | AGTR2 (0.82) | AGTR1AGTR2NPY2RNPY4RNPY5R | |
| Angiotensin Ii SCHEMBL2566771 | 0.86 | AGTR2 (0.84) | AGTR1AGTR2REN | |
| Angiotensin Ii SCHEMBL1189 | 0.86 | AGTR2 (0.84) | AGTR1AGTR2REN | |
| Angiotensin Ii SCHEMBL13232382 | 0.86 | AGTR2 (0.84) | AGTR1AGTR2REN | |
| Angiotensin Ii SCHEMBL14990505 | 0.86 | AGTR2 (0.83) | AGTR1AGTR2REN | |
| Angiotensin Ii SCHEMBL21267957 | 0.86 | AGTR2 (0.83) | AGTR1AGTR2REN | |
| Angiotensin Ii SCHEMBL3465991 | 0.86 | AGTR2 (0.83) | AGTR1AGTR2REN | |
| SCHEMBL30950135 | 0.86 | CALCR (0.57) | NPY2RNPY4RNPY5RNPY1R | |
| Isracidin SCHEMBL29668326 | 0.86 | NPY2R (0.70) | NPY2RNPY4RNPY5RNPY1RTFPI | |
| Angiotensin Ii SCHEMBL3044639 | 0.86 | AGTR2 (0.81) | AGTR1AGTR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2023196958-A2 | TUMOR AND CANCER TARGETING COMPOUNDS | ONCOLINX PHARMACEUTICALS (US) | 2023-10-12 | — | — | WO | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4342543-B1 | TERT-BUTYL 2-(4-PHENYL-6H-THIENO[3,2-F][1,2,4]TRIAZOLO[4,3-A] [1,4]DIAZEPIN-6-YL) ACETATE DERIVATIVES AS BROMODOMAIN BRD4 INHIBITORS FOR TREATING CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-04-28 | — | — | US | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-12569556-B2 | Aluminum based adjuvants for tolerogenic vaccination | EAST CAROLINA UNIVERSITY (US) | 2026-03-10 | — | — | US | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| EP-3464270-B1 | HETEROCYCLIC INHIBITORS OF CBP/EP300 AND THEIR USE IN THE TREATMENT OF CANCER | GENENTECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220049275-A1 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LONZA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-11247989-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220042064-A1 | CARBON-SOURCE REGULATED PROTEIN PRODUCTION IN A RECOMBINANT HOST CELL | LONZA LTD (CH) | 2022-02-10 | — | — | US | disclosed |
| EP-3947695-A1 | MUT- METHYLOTROPHIC YEAST | Universität für Bodenkultur Wien (AT) | 2022-02-09 | — | — | EP | disclosed |
| CN-114026239-A | MUT-methanol nutritional yeast | 维也纳自然资源与生命科学大学 | 2022-02-08 | — | — | CN | disclosed |
| US-11236520-B2 | Customizable facility | LONZA LTD (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3942014-A1 | CONTINUOUS BLADE IMPELLER | Lonza Ltd. (CH) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | AGTR1 580/4885AGTR2 617/4885NPY2R 111/4885 |
| US-12612631-B2 | Small RNA medicament for prevention and treatment of inflammation-related diseases and combination thereof | EIF2AK2, IL1A, IRF3 | AGTR1 1139/4885AGTR2 1628/4885NPY2R 4355/4885 |
| US-11247989-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, CREBBP | AGTR1 669/4885AGTR2 839/4885NPY2R 772/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | AGTR1 60/4885AGTR2 95/4885NPY2R 84/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | AGTR1 312/4885AGTR2 526/4885NPY2R 150/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | AGTR1 883/4885AGTR2 1608/4885NPY2R 1754/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | AGTR1 521/4885AGTR2 595/4885NPY2R 1961/4885 |
| US-12569556-B2 | Aluminum based adjuvants for tolerogenic vaccination | IFNG, MYH2, MYH10 | AGTR1 1843/4885AGTR2 2294/4885NPY2R 4027/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | AGTR1 539/4885AGTR2 1134/4885NPY2R 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.